Adcock Ingram is a leading South African pharmaceutical manufacturer, marketer and distributor. The company occupies 10% share of the private pharmaceutical market in South Africa with a strong presence in over-the-counter (OTC) brands. Adcock is als... More
LUPIN ADCOCK INGRAM |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
LUPIN Mar-23 |
ADCOCK INGRAM Jun-14 |
LUPIN/ ADCOCK INGRAM |
5-Yr Chart Click to enlarge
|
||
High | Rs | 799 | 317 | - | |
Low | Rs | 583 | 229 | - | |
Sales per share (Unadj.) | Rs | 365.8 | 94.2 | - | |
Earnings per share (Unadj.) | Rs | 9.8 | -23.7 | - | |
Cash flow per share (Unadj.) | Rs | 29.2 | -19.7 | - | |
Dividends per share (Unadj.) | Rs | 4.00 | 0 | - | |
Avg Dividend yield | % | 0.6 | 0 | - | |
Book value per share (Unadj.) | Rs | 270.7 | 74.0 | - | |
Shares outstanding (eoy) | m | 454.98 | 168.78 | - | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 1.9 | 2.9 | 65.3% | |
Avg P/E ratio | x | 70.2 | -11.5 | -611.6% | |
P/CF ratio (eoy) | x | 23.7 | -13.9 | -170.8% | |
Price / Book Value ratio | x | 2.6 | 3.7 | 69.2% | |
Dividend payout | % | 40.7 | 0 | - | |
Avg Mkt Cap | Rs m | 314,381 | 46,024 | 683.1% | |
No. of employees | `000 | NA | 4.3 | 0.0% | |
Total wages/salary | Rs m | 30,872 | 2,889 | 1,068.7% | |
Avg. sales/employee | Rs Th | 0 | 3,705.3 | - | |
Avg. wages/employee | Rs Th | 0 | 672.9 | - | |
Avg. net profit/employee | Rs Th | 0 | -933.7 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 166,417 | 15,907 | 1,046.2% | |
Other income | Rs m | 1,509 | 111 | 1,354.8% | |
Total revenues | Rs m | 167,926 | 16,018 | 1,048.3% | |
Gross profit | Rs m | 17,206 | -2,757 | -624.2% | |
Depreciation | Rs m | 8,807 | 687 | 1,282.8% | |
Interest | Rs m | 2,743 | 431 | 636.6% | |
Profit before tax | Rs m | 7,165 | -3,763 | -190.4% | |
Minority Interest | Rs m | 0 | -10 | -0.0% | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | 2,688 | 235 | 1,143.3% | |
Profit after tax | Rs m | 4,477 | -4,008 | -111.7% | |
Gross profit margin | % | 10.3 | -17.3 | -59.7% | |
Effective tax rate | % | 37.5 | -6.2 | -600.4% | |
Net profit margin | % | 2.7 | -25.2 | -10.7% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 124,513 | 11,650 | 1,068.7% | |
Current liabilities | Rs m | 92,654 | 6,555 | 1,413.5% | |
Net working cap to sales | % | 19.1 | 32.0 | 59.8% | |
Current ratio | x | 1.3 | 1.8 | 75.6% | |
Inventory Days | Days | 26 | 111 | 23.6% | |
Debtors Days | Days | 98 | 124 | 79.3% | |
Net fixed assets | Rs m | 103,490 | 6,791 | 1,523.9% | |
Share capital | Rs m | 910 | 74 | 1,232.2% | |
Net worth | Rs m | 123,156 | 12,485 | 986.4% | |
Long term debt | Rs m | 275 | 4,387 | 6.3% | |
Total assets | Rs m | 228,003 | 23,585 | 966.7% | |
Interest coverage | x | 3.6 | -7.7 | -46.7% | |
Debt to equity ratio | x | 0 | 0.4 | 0.6% | |
Sales to assets ratio | x | 0.7 | 0.7 | 108.2% | |
Return on assets | % | 3.2 | -15.2 | -20.9% | |
Return on equity | % | 3.6 | -32.1 | -11.3% | |
Return on capital | % | 8.0 | -19.8 | -40.5% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 18,972 | 1,358 | 1,397.3% | |
From Investments | Rs m | -12,868 | -417 | 3,086.5% | |
From Financial Activity | Rs m | -3,373 | 3,982 | -84.7% | |
Net Cashflow | Rs m | 2,732 | 4,923 | 55.5% |
Compare LUPIN With: ACTAVIS (US) MYLAN (US) TEVA PHARMA (Israel)
Compare LUPIN With: ORTIN LABS JENBURKT PH. DENIS CHEM LAB LYKA LABS SAROJA PHARMA INDUSTRIES INDIA LTD.
After opening the day deep in red, Indian share markets reversed the trend as the session progressed and ended on firm footing.